Laurocapram
Based on 1 publication(s) in Google Scholar
Laurocapram is a chemical penetration enhancer that increases the permeability of compounds through the skin and mucous membranes, thereby improving their local or systemic efficacy. Laurocapram improves the skin permeability of a variety of hydrophilic and lipophilic compounds.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.36%
- CAS. Nr.: 59227-89-3
- Formel: C18H35NO
- Molecular Weight:281.48
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Laurocapram
More
Biologische Aktivität
Laurocapram (16-64 μg/mL, 24 h) synergizes with β-lactam antibiotics, such as Cefixime (HY-B1381), Penicillin G (HY-N7139) and Polymyxin E (HY-A0089), and improves their antibacterial activity against S. aureus, especially MRSA strains[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MRSA-infected mouse models[2]
-
Dosage:50 mg/kg laurocapram+cefixime combination
-
Administration:ip, every 12 hours for 3 doses
-
Result:Alleviated the pathological changes of lung tissue, reduced the pulmonary edema and the bacterial load.
Reduced the The area of skin infection wounds, reduced levels of FN-γ, IL-6 and TNF-α.
Chemical Information
-
CAS. Nr. 59227-89-3
-
Appearance Liquid (Density: 0.906-0.926 g/cm3)
-
Molecular Weight 281.48
-
Formel C18H35NO
-
Color Colorless to light yellow
-
SMILES
O=C1N(CCCCCCCCCCCC)CCCCC1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (355.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. López-Cervantes M, et al. Chemical enhancers for the absorption of substances through the skin: Laurocapram and its derivatives. Drug Dev Ind Pharm. 2006 Mar;32(3):267-86. [Content Brief]
[2]. Wang N, et al., Laurocapram, a transdermal enhancer, boosts cephalosporin's antibacterial activity against Methicillin-resistant Staphylococcus aureus. Biochem Pharmacol. 2024 Sep;227:116404. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5527 mL | 17.7633 mL | 35.5265 mL | 88.8163 mL |
| 5 mM | 0.7105 mL | 3.5527 mL | 7.1053 mL | 17.7633 mL | |
| 10 mM | 0.3553 mL | 1.7763 mL | 3.5527 mL | 8.8816 mL | |
| 15 mM | 0.2368 mL | 1.1842 mL | 2.3684 mL | 5.9211 mL | |
| 20 mM | 0.1776 mL | 0.8882 mL | 1.7763 mL | 4.4408 mL | |
| 25 mM | 0.1421 mL | 0.7105 mL | 1.4211 mL | 3.5527 mL | |
| 30 mM | 0.1184 mL | 0.5921 mL | 1.1842 mL | 2.9605 mL | |
| 40 mM | 0.0888 mL | 0.4441 mL | 0.8882 mL | 2.2204 mL | |
| 50 mM | 0.0711 mL | 0.3553 mL | 0.7105 mL | 1.7763 mL | |
| 60 mM | 0.0592 mL | 0.2961 mL | 0.5921 mL | 1.4803 mL | |
| 80 mM | 0.0444 mL | 0.2220 mL | 0.4441 mL | 1.1102 mL | |
| 100 mM | 0.0355 mL | 0.1776 mL | 0.3553 mL | 0.8882 mL |
Laurocapram Related Classifications
HY-W009326 Related Classifications
Powered by Bioz